Advertisement
Singapore markets close in 3 hours 57 minutes
  • Straits Times Index

    3,305.96
    +2.77 (+0.08%)
     
  • Nikkei

    38,797.88
    +561.81 (+1.47%)
     
  • Hang Seng

    18,420.38
    -157.92 (-0.85%)
     
  • FTSE 100

    8,213.49
    +41.34 (+0.51%)
     
  • Bitcoin USD

    63,433.29
    -738.87 (-1.15%)
     
  • CMC Crypto 200

    1,363.28
    +50.65 (+3.86%)
     
  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     
  • Dow

    38,852.27
    +176.59 (+0.46%)
     
  • Nasdaq

    16,349.25
    +192.92 (+1.19%)
     
  • Gold

    2,330.90
    -0.30 (-0.01%)
     
  • Crude Oil

    78.60
    +0.12 (+0.15%)
     
  • 10-Yr Bond

    4.4890
    -0.0110 (-0.24%)
     
  • FTSE Bursa Malaysia

    1,609.36
    +11.97 (+0.75%)
     
  • Jakarta Composite Index

    7,133.40
    -2.50 (-0.03%)
     
  • PSE Index

    6,640.31
    -12.18 (-0.18%)
     

Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?

Wall Street Says This Growth Stock Is a Buy, but Is It Overvalued?

A struggling economy and a bear market haven't been able to stop Vertex Pharmaceuticals (NASDAQ: VRTX). Vertex's forward multiple comes in at more than four times the upper bounds of this range. Also, the company's forward price-to earnings (P/E) multiple is higher than that of the biotech industry, which is currently about 15.